ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event
12 January 2023 - 6:45AM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a
clinical-stage specialty biopharmaceutical company developing
first-in-class drugs for treatment of renal and inflammatory
diseases with high unmet medical needs, today announced that
Stephen C. Glover, ZyVersa’s Co-founder, Chairman, Chief Executive
Officer, and President, will present at the Virtual Investor 2023
Companies to Watch Event on Wednesday, January 18, 2023 at 2:00 PM
ET.
A live video webcast of the presentation will be available on
the Events page of ZyVersa’s website (www.zyversa.com). A webcast
replay will be available two hours following the live presentation
and will be accessible for 90 days.
“As a newly traded company on Nasdaq under the ticker “ZVSA,” we
are excited to discuss ZyVersa’s potential to build stockholder
value as we advance the clinical program for our cholesterol efflux
mediator (VAR 200) for renal disease, and our IND-enabling
initiatives for our differentiated inflammasome ASC inhibitor IC
100,” stated Mr. Glover.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company
leveraging advanced, proprietary technologies to develop
first-in-class drugs. Our focus is on patients with renal or
inflammatory diseases who have significant unmet medical needs. Our
development pipeline includes phase 2a-ready VAR 200, a cholesterol
efflux mediator for treatment of rare kidney disease, focal
segmental glomerulosclerosis (FSGS). VAR 200 has potential to treat
other kidney diseases, such as Alport Syndrome and Diabetic Kidney
Disease. It also includes a novel inflammasome ASC inhibitor with
potential to treat multiple CNS and other inflammatory diseases.
For more information, please visit www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate and IR Contact:Karen CashmereChief
Commercial
Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic
Advisors, Inc.Casey
McDonaldcmcdonald@tiberend.com646-577-8520
Dave SchemeliaDschemelia@tiberend.com609-468-9325
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/bc7ca541-cbf1-4026-a4cb-2908fcb57793
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Sep 2024 to Oct 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Oct 2023 to Oct 2024